Long Non-coding RNA RUNDC3A-AS1 Promotes Lung Metastasis of Thyroid Cancer via Targeting the miR-182-5p/ADAM9

Abstract

Long non-coding RNAs (lncRNAs) have been identified as influential indicators in variety of malignancies. Among which, LncRNA RUNDC3A-AS1 is reported to upregulate in thyroid cancer. However, the expression pattern and the pathological function of lncRNA RUNDC3A-AS1 in thyroid cancer is unclear. In this study, we examined the expression levels of lncRNA RUNDC3A-AS1 in the thyroid cancer tissues and cell lines via RT-qPCR analysis. The effects of RUNDC3A-AS1 on thyroid cancer cell metastasis were detected by transwell chamber assay, scratch assay in vitro and lung metastasis model in vivo. The results indicated that RUNDC3A-AS1 was highly expressed in the thyroid cancer tissues and cell lines. Functionally, knockdown of RUNDC3A-AS1 could repress the migration and invasion of thyroid cancer cells in vitro, and inhibit thyroid cancer metastasis to lung in vivo. Mechanistically, RUNDC3A-AS1 served as an inhibitor of miR-182-5p in tumor tissues and cell lines. RUNDC3A-AS1 inhibited the expression of miR-182-5p to increase the expression level of ADAM9, thus further aggravating the malignancy of thyroid cancer. Therefore, the RUNDC3A-AS1/miR-182-5p/ADAM9 axis may be a potential therapeutic target for the treatment of thyroid cancer metastasis.

LINC00115 aggravates thyroid cancer progression by targeting miR-489-3p, which downregulates EVA1A to regulate the Hippo signaling pathway

“…In many cancers, long non-coding RNAs (lncRNAs) of >200 nt are pivotal regulators [ 6 ]. This is supported by evidence that an increase in the expression levels of lncRNAs, including RUNDC3A-AS1 [ 7 ], CCDC26 [ 8 ], XIST [ 9 ], and TUG1 [ 10 ] leads to an unfavorable THCA prognosis. LINC00115 , an lncRNA, was originally identified as a possible biomarker for bladder [ 11 ] and lung cancers [ 12 ].…”

Upregulation of XIAP promotes lung adenocarcinoma brain metastasis by modulating ceRNA network

“…SBF2-AS1 can also affect the malignant phenotype of non-small cell lung cancer (NSCLC) by participating in miR-338-3p/ADAM17 axis (37). However, RUNDC3A-AS1 has not been extensively studied, and it was currently discovered that RUNDC3A-AS1 regulated the malignant progression of thyroid cancer and can promote lung metastasis by targeting miR-182-5p/ADAM9 (38,39). New research has shown that miR-338-3p suppresses the metastasis of lung cancer by influencing the MAPK signaling pathway or targeting KIF2A (40,41).…”